Benzimidazoles Against Certain Breast Cancer Drug Targets: A Review

KIŞLA M. M., ALAGÖZ Z.

MINI-REVIEWS IN MEDICINAL CHEMISTRY, cilt.22, sa.19, ss.2463-2477, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 22 Sayı: 19
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2174/1389557522666220328161217
  • Dergi Adı: MINI-REVIEWS IN MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2463-2477
  • Anahtar Kelimeler: Anticancer drugs, benzimidazoles, target-based biomolecules, pathways, plethora of pathways, breast cancer, GROWTH-FACTOR RECEPTOR, RANDOMIZED PHASE-II, ESTROGEN-RECEPTOR, BIOLOGICAL EVALUATION, AROMATASE INHIBITORS, THERAPY, MTOR, SIRT1, PI3K, ABEMACICLIB
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Benzimidazoles are widely used scaffolds against various types of cancer, including breast cancer. To this end, anticancer agents must be developed using the knowledge of the specific targets of BC. Objective: In this study, we aim to review the compounds used against some of the biomolecular targets of breast cancer. To this end, we present information about the various targets, with their latest innovative studies. Conclusion: Benzimidazole ring is an important building block that can target diverse cancer scenarios since it can structurally mimic biomolecules in the human body. Additionally, many studies imply the involvement of this moiety on a plethora of pathways and enzymes related to BC. Herein, our target-based collection of benzimidazole derivatives strongly suggests the utilization of benzimidazole derivatives against BC.